Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132323 | 0.76 | CYP3A4 (0.39) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23198970 | 0.70 | MAPT (0.47) | CYP3A4KDM4EMEN1MAPTKMT2A | |
| SCHEMBL5820346 | 0.69 | MEN1 (0.47) | CYP3A4KDM4EMEN1MAPTKMT2A | |
| SCHEMBL29709363 | 0.69 | PIM1 (0.69) | CYP3A4KDM4EMEN1MAPTKMT2A | |
| Austrocortirubin SCHEMBL23199031 | 0.68 | LCK (0.56) | CYP3A4KDM4EMEN1MAPTKMT2A | |
| Austrocortirubin SCHEMBL29357393 | 0.68 | LCK (0.56) | CYP3A4KDM4EMEN1MAPTKMT2A | |
| SCHEMBL23199058 | 0.67 | PIM1 (0.49) | CYP3A4KDM4EMEN1MAPTKMT2A | |
| SCHEMBL5821593 | 0.66 | PTGS2 (0.39) | CYP3A4KDM4EMEN1MAPTKMT2A | |
| SCHEMBL5820540 | 0.66 | PTGS2 (0.39) | CYP3A4KDM4EMEN1MAPTKMT2A | |
| SCHEMBL18971654 | 0.66 | STAT3 (0.54) | CYP3A4KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250360073-A1 | SOLUBILIZING PIGMENTS EXTRACTED FROM FUNGI FOR APPLICATIONS SUCH AS COSMETIC PRODUCTS | ADLER JESSE (US) | 2025-11-27 | — | — | US | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | disclosed |
| WO-2002100478-A2 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1261254-A2 | METHOD OF CONTROLLING ZOOLOGICAL AND AQUATIC PLANT GROWTH | Garnett, Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020098979-A1 | Method of controlling zoological and aquatic plant growth | CUTLER STEPHEN J (US) | 2002-07-25 | — | — | US | disclosed |
| US-20020098978-A1 | Method of controlling zoological and aquatic plant growth | CUTLER STEPHEN J (US) | 2002-07-25 | — | — | US | disclosed |
| US-6340468-B1 | KILLING A TARGET AQUATIC PEST SELECTED FROM VIRUSES, PROTISTS, FUNGI, MOLDS, PLANTS, HOLOPLANKTONIC ORGANISMS, MEROPLANKTONIC ORGANISMS, DEMERSAL ORGANISMS, BENTHIC ORGANISMS, ECT., BY APPLYING NAPHTHALENEDIONE COMPOUND | GARNETT, INC. | 2002-01-22 | — | — | US | disclosed |
| WO-2001060971-A2 | METHOD OF CONTROLLING ZOOLOGICAL AND AQUATIC PLANT GROWTH | GARNETT, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-0234431-A2 | 5-Hydroxydihydrofusarubin, a process for its preparation and its use for the preparation of a medicament | HOECHST JAPAN LIMITED (JP) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | CYP3A4 3571/4885KDM4E 4637/4885MEN1 1711/4885 |
| US-20020098978-A1 | Method of controlling zoological and aquatic plant growth | ANTXR2, AQP1, AQP3 | CYP3A4 2936/4885KDM4E 3300/4885MEN1 3800/4885 |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | CYP3A4 3252/4885KDM4E 4365/4885MEN1 593/4885 |
| US-20020098979-A1 | Method of controlling zoological and aquatic plant growth | ANTXR2, NQO2, CYP4A22 | CYP3A4 164/4885KDM4E 2692/4885MEN1 3909/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | CYP3A4 1840/4885KDM4E 3795/4885MEN1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.